Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

7.080 +0.390 (+5.83%)

Streaming Delayed Price Updated: 11:16 AM EDT, Jun 4, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	553,807
Open	6.770
Bid (Size)	7.070 (500)
Ask (Size)	7.090 (300)
Prev. Close	6.690
Today's Range	6.700 - 7.180
52wk Range	5.455 - 16.19
Shares Outstanding	43,466,186
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Regenxbio (RGNX) Q1 2026 Earnings Transcript ↗

May 18, 2026

Regenxbio (RGNX) Q1 2026 Earnings Transcript

Via The Motley Fool

These stocks are moving in today's session ↗

May 14, 2026

Via Chartmill

Performance

YTD	-47.8%	-47.8%
1 Month	-24.6%	-24.6%
3 Month	-22.5%	-22.5%
6 Month	-45.0%	-45.0%
1 Year	-30.1%	-30.1%

More News

What's going on in today's session ↗

May 14, 2026

Via Chartmill

Which stocks are gapping on Thursday? ↗

May 14, 2026

Via Chartmill

REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results ↗

May 14, 2026

Via Chartmill

Discover the top movers in Thursday's pre-market session. ↗

May 14, 2026

Via Chartmill

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

April 14, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

April 14, 2026

From The Rosen Law Firm, P.A.

Via Business Wire

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

April 14, 2026

From Faruqi & Faruqi, LLP

Via Business Wire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 13, 2026

From Schall Law

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 09, 2026

From Schall Law

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

April 07, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 06, 2026

From Schall Law

Via GlobeNewswire

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

April 05, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX

April 04, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm

April 03, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

April 02, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

April 02, 2026

From Schall Law

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

March 31, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 30, 2026

From Schall Law

Via GlobeNewswire

The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH

March 26, 2026

Via Finterra

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP

March 24, 2026

From Levi & Korsinsky, LLP

Via Business Wire

RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

March 24, 2026

From Faruqi & Faruqi LLP

Via GlobeNewswire

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

March 23, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?

Yes, REGENXBIO Inc. - Common Stock is publicly traded.

What exchange does REGENXBIO Inc. - Common Stock trade on?

REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for REGENXBIO Inc. - Common Stock?

The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market

What is the current price of REGENXBIO Inc. - Common Stock?

The current price of REGENXBIO Inc. - Common Stock is 7.080

When was REGENXBIO Inc. - Common Stock last traded?

The last trade of REGENXBIO Inc. - Common Stock was at 06/04/26 11:16 AM ET

What is the market capitalization of REGENXBIO Inc. - Common Stock?

The market capitalization of REGENXBIO Inc. - Common Stock is 307.74M

How many shares of REGENXBIO Inc. - Common Stock are outstanding?

REGENXBIO Inc. - Common Stock has 308M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.